Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | GLI1 | P08151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248747 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL248746 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Bromide SCHEMBL27517782 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL596114 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL661790 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL661789 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL2804278 | 0.95 | SCN9A (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Oxalic Acid SCHEMBL9353931 | 0.95 | DPP4 (0.40) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL7384758 | 0.95 | SCN9A (0.37) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL7384762 | 0.95 | SCN9A (0.37) | NOS2NOS3NOS1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1131 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-11786860-B2 | Solvent composition for CO2 capture and a process mediated thereof | INDIAN OIL CORPORATION LIMITED (IN) | 2023-10-17 | — | — | US | claimed |
| CN-116874449-A | (R) -4-propyl-dihydrofuran-2-one and purification method and application thereof | 四川奥邦古得药业有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-110339351-B | Preparation method of rabies inactivated vaccine for livestock and stabilizer contained in vaccine | 武汉科前生物股份有限公司 | 2023-02-14 | — | — | CN | claimed |
| CN-112010822-B | Method for preparing chiral gamma-amino alcohol and chiral alpha-allyl alcohol by one-pot method | 南方科技大学 | 2022-11-18 | — | — | CN | claimed |
| US-20220072472-A1 | SOLVENT COMPOSITION FOR CO2 CAPTURE AND A PROCESS MEDIATED THEREOF | INDIAN OIL CORPORATION LIMITED (IN) | 2022-03-10 | — | — | US | claimed |
| EP-3964279-A1 | SOLVENT COMPOSITION FOR CO2 CAPTURE AND A PROCESS MEDIATED THEREOF | Indian Oil Corporation Limited (IN) | 2022-03-09 | — | — | EP | claimed |
| CN-110339351-A | The stabilizer that a kind of preparation method of veterinary rabies inactivated vaccine and the vaccine include | 武汉科前生物股份有限公司 | 2019-10-18 | — | — | CN | claimed |
| US-9796784-B2 | Methods and compositions for the generation and use of conformation-specific antibodies | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-10-24 | — | — | US | claimed |
| CN-106083729-A | A kind of synthetic method of benzimidazoles compound | 王建军 | 2016-11-09 | — | — | CN | claimed |
| US-20140242100-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-08-28 | — | — | US | claimed |
| WO-2012149334-A2 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-11-01 | — | — | WO | claimed |
| WO-2011056561-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-05-12 | — | — | WO | claimed |
| US-20060120980-A1 | Novel dermatological composition using bio-activating organocatalysts | EBERSYTES, LLC | 2006-06-08 | — | — | US | claimed |
| EP-0557936-A1 | Amidic derivatives of (R)-glycerophosphoryl-(S)-serine or of its diacyl derivative, process for their preparation and relative pharmaceutical compositions for the improvement of the learning processes | MAGIS FARMACEUTICI S.p.A. (IT) | 1993-09-01 | — | — | EP | claimed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | claimed |
| US-4308168-A | ALKYLESTERS OF AMINO ACIDS, NONTOXIC | IDEMITSU KOSAN CO., LTD. (JP) | 1981-12-29 | — | — | US | claimed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4695259-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| CN-120943886-B | Synthesis method of tripeptide Fmoc-Pro-Pro-Pro-OH | 浙江肽昇生物医药有限公司 | 2026-01-30 | — | — | CN | disclosed |
| EP-4678652-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4674839-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | CK Regeon Inc. (KR) | 2026-01-07 | — | — | EP | disclosed |
| US-12516022-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250382264-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | AICHI STEEL CORPORATION (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-120943886-A | Synthesis method of tripeptide Fmoc-Pro-Pro-Pro-OH | 浙江肽昇生物医药有限公司 | 2025-11-14 | — | — | CN | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4635494-A2 | AMIDO HETEROAROMATIC COMPOUNDS | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| EP-4384223-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4514782-B1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| WO-2025132542-A1 | MACROCYCLIC OREXIN AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4570813-A1 | METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-18 | — | — | EP | disclosed |
| CN-120136962-A | Fibroblast activation protein targeting compound, nuclide marker thereof, pharmaceutical composition containing same and application | 潍坊市人民医院(潍坊市公共卫生临床中心、潍坊市职业病医院) | 2025-06-13 | — | — | CN | disclosed |
| US-12291524-B2 | Amido heteroaromatic compounds | ASTRAZENECA AB (SE) | 2025-05-06 | — | — | US | disclosed |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| WO-2025070753-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | 中外製薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| CN-119707995-A | Preparation method of natural alkaloid (+) -RHYNCHINE E compound | 郑州大学 | 2025-03-28 | — | — | CN | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4514782-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| CN-113795249-B | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250059183-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | SHANGHAI VISONPHARMA CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4505875-A1 | METHOD FOR CONTROLLING PARASITIC PLANTS | AJINOMOTO CO., INC. (JP) | 2025-02-12 | — | — | EP | disclosed |
| EP-4501909-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | Aichi Steel Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20250031699-A1 | Method for Controlling Parasitic Plants | AJINOMOTO CO., INC. (JP) | 2025-01-30 | — | — | US | disclosed |
| CN-119330800-A | Method for directly synthesizing beta-acyloxy enamide compound by three components and application thereof | 江西师范大学 | 2025-01-21 | — | — | CN | disclosed |
| WO-2025012195-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2025-01-09 | — | — | US | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240399776-A1 | COLOR DEVELOPER, THERMAL RECORDING MATERIAL, AND THERMAL RECORDING LAYER COATING MATERIAL | SANKO CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-119039187-A | Synthesis method of amino acid substituted N-sulfonyl amidine derivative | 西南民族大学 | 2024-11-29 | — | — | CN | disclosed |
| CN-119012914-A | Method for controlling parasitic plants | 味之素株式会社 | 2024-11-22 | — | — | CN | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| WO-2024219480-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2024-10-24 | — | — | WO | disclosed |
| WO-2024213610-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| EP-4446323-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | Shanghai Visonpharma Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-116675653-B | Aminoalkyl substituted 1,2, 4-thiadiazolidine-3, 5-dione compound, preparation method and application thereof | 中国药科大学 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024181799-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | 주식회사 씨케이리제온 | 2024-09-06 | — | — | WO | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4412991-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-118317948-A | Derivatives of aromatic hydrocarbon receptor agonists | 阿佐拉治疗股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024138486-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240209020-A1 | REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4384224-A1 | CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| CN-113453762-B | Pentacyclic heterocyclic compounds | 卫材R&D管理有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240182416-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-118103074-A | Cytotoxic targeting chimeras for CCR2 expressing cells | 葛兰素史克知识产权发展有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024103178-A1 | ANISOMYCIN ANALOGS AND USES THEREOF | Université de Montréal (CA) | 2024-05-23 | — | — | WO | disclosed |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2024103016-A1 | 4'-HALOMETHYL-CYTIDINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024080333-A1 | METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2024-04-18 | — | — | WO | disclosed |
| US-20240115719-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | AJINOMOTO CO., INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| CN-112745298-B | Polysubstituted isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-04-09 | — | — | CN | disclosed |
| US-20240091370-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2024051721-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4323338-A1 | TEAD INHIBITORS | Orion Corporation (FI) | 2024-02-21 | — | — | EP | disclosed |
| CN-115066423-B | PD-L1 antagonist compounds | 厦门宝太生物科技股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024022167-A1 | CAMPTOTHECIN DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | 杭州爱科瑞思生物医药有限公司 | 2024-02-01 | — | — | WO | disclosed |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| EP-4306535-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED USING SAME | AJINOMOTO CO., INC. (JP) | 2024-01-17 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| EP-4301363-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | Nikang Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11866418-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117255684-A | Quinazolinamine derivatives as KRAS inhibitors | 尼坎治疗公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117203198-A | Compounds as PU.1 inhibitors | 浙江星浩澎博医药有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230348578-A1 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4269119-A1 | COLOR DEVELOPER, HEAT-SENSITIVE RECORDING MATERIAL, AND COATING MATERIAL FOR HEAT-SENSITIVE RECORDING LAYERS | Sanko Co., Ltd. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116964076-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-10-27 | — | — | CN | disclosed |
| US-11786860-B2 | Solvent composition for CO2 capture and a process mediated thereof | INDIAN OIL CORPORATION LIMITED (IN) | 2023-10-17 | — | — | US | disclosed |
| CN-116874449-A | (R) -4-propyl-dihydrofuran-2-one and purification method and application thereof | 四川奥邦古得药业有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023195475-A1 | METHOD FOR CONTROLLING PARASITIC PLANTS | 味の素株式会社 | 2023-10-12 | — | — | WO | disclosed |
| WO-2023190156-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | 愛知製鋼株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230303510-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-4247805-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmceuticals (CN) | 2023-09-27 | — | — | EP | disclosed |
| US-20230287093-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES | PINTEON THERAPEUTICS INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116744978-A | anti-HER 2 immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116675653-A | Aminoalkyl substituted 1,2, 4-thiadiazolidine-3, 5-dione compound, preparation method and application thereof | 中国药科大学 | 2023-09-01 | — | — | CN | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116554068-A | Preparation method of thio-polypeptide | 西安交通大学 | 2023-08-08 | — | — | CN | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-115197167-B | 1,2, 4-thiadiazolidine-3, 5-dione compound, and preparation method and application thereof | 中国药科大学 | 2023-07-28 | — | — | CN | disclosed |
| CN-116478174-A | Camptothecin derivative, and preparation method and application thereof | 杭州爱科瑞思生物医药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3615502-B1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIV TASMANIA (AU) | 2023-06-21 | — | — | EP | disclosed |
| EP-3786151-B1 | METHOD FOR PRODUCING AMIDE COMPOUND | CHUBU UNIV EDUCATIONAL FOUNDATION (JP) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023097031-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| CN-112020492-B | Method for producing amide compound | 学校法人中部大学 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| EP-3464317-B1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIV LAVAL (CA) | 2023-04-26 | — | — | EP | disclosed |
| EP-3464317-B1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIV LAVAL (CA) | 2023-04-26 | — | — | EP | disclosed |
| US-20230121469-A1 | CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2023-04-20 | — | — | US | disclosed |
| WO-2023060268-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20230099716-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| US-20230100065-A1 | COMPOUNDS FOR USE IN PCR SYSTEMS AND APPLICATIONS THEREOF | Life Technologies Corporation | 2023-03-30 | — | — | US | disclosed |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-09 | — | — | US | disclosed |
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-09 | — | — | US | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-11591385-B2 | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies | PINTEON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2023017484-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017483-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| CN-110339351-B | Preparation method of rabies inactivated vaccine for livestock and stabilizer contained in vaccine | 武汉科前生物股份有限公司 | 2023-02-14 | — | — | CN | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11512108-B2 | Method for producing amide compound | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2022-11-29 | — | — | US | disclosed |
| US-11505545-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-22 | — | — | US | disclosed |
| CN-109890793-B | Novel anthelmintic quinoline-3-carboxamide derivatives | 拜耳动物保健有限责任公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-112010822-B | Method for preparing chiral gamma-amino alcohol and chiral alpha-allyl alcohol by one-pot method | 南方科技大学 | 2022-11-18 | — | — | CN | disclosed |
| US-20220356166-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-11-10 | — | — | US | disclosed |
| EP-3615524-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220348645-A1 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-11-03 | — | — | US | disclosed |
| EP-4083032-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2022-11-02 | — | — | EP | disclosed |
| CN-115232109-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业有限公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| CN-115197167-A | 1,2,4-thiadiazolidine-3,5-diketone compound and preparation method and application thereof | 中国药科大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-115093438-A | Process for the synthesis of intermediates and intermediates | 中国原子能科学研究院 | 2022-09-23 | — | — | CN | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| CN-115066423-A | PD-L1 antagonist compounds | 杭州阿诺生物医药科技有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2022191283-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED USING SAME | 味の素株式会社 | 2022-09-15 | — | — | WO | disclosed |
| CN-115043864-A | Process for the synthesis of intermediates and intermediates | 中国原子能科学研究院 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022187528-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022187527-A1 | QUINAZOLINE NITRILE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4053101-A1 | REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME | Chubu University Educational Foundation (JP) | 2022-09-07 | — | — | EP | disclosed |
| CN-115010739-A | Method for synthesizing F-BPA | 中国原子能科学研究院 | 2022-09-06 | — | — | CN | disclosed |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2022-08-25 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-07-14 | — | — | US | disclosed |
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-07-14 | — | — | US | disclosed |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114667167-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220195066-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| CN-108201625-B | Linker drugs and antibody drug complexes comprising the same | 财团法人工业技术研究院 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022105825-A1 | COMPOUNDS AS PU. 1 INHIBITORS | PEKING UNIVERSITY (CN) | 2022-05-27 | — | — | WO | disclosed |
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2022051489-A1 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220072472-A1 | SOLVENT COMPOSITION FOR CO2 CAPTURE AND A PROCESS MEDIATED THEREOF | INDIAN OIL CORPORATION LIMITED (IN) | 2022-03-10 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3964279-A1 | SOLVENT COMPOSITION FOR CO2 CAPTURE AND A PROCESS MEDIATED THEREOF | Indian Oil Corporation Limited (IN) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962888-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3939658-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939658-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| CN-113825740-A | Itaconic acid derivatives and their use in the treatment of inflammatory diseases or diseases associated with adverse immune reactions | 西特瑞治疗有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-11203586-B2 | Iridinesulfonamide compound and use method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-21 | — | — | US | disclosed |
| CN-113677399-A | Bivalent antagonists of inhibitor of apoptosis proteins | 和博医药有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | UNIVERSITé LAVAL (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| CN-113453762-A | Pentacyclic heterocyclic compounds | 卫材R&D管理有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210284653-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210221786-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-22 | — | — | US | disclosed |
| US-20210221786-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-22 | — | — | US | disclosed |
| EP-3687506-B1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3687506-B1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2021129584-A1 | PD-L1 ANTAGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-11046695-B2 | Fragment synthesis of substituted cyclic peptides | ZEALAND PHARMA A/S (DK) | 2021-06-29 | — | — | US | disclosed |
| EP-3342599-B1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO LTD (JP) | 2021-06-16 | — | — | EP | disclosed |
| CN-112912371-A | Flavone derivatives for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-11021458-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210155610-A1 | Iridinesulfonamide Compound And Use Method Thereof | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| CN-107074820-B | GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112745298-A | Polysubstituted isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-05-04 | — | — | CN | disclosed |
| US-10981921-B2 | Fragment synthesis of substituted cyclic peptides | ZEALAND PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| WO-2021067628-A2 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3137470-B1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| CN-109071429-B | Prophyridine sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| US-10941159-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| CN-112457301-A | Novel GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10934253-B2 | Therapeutic compounds and methods | UNIVERSITY OF TASMANIA (AU) | 2021-03-02 | — | — | US | disclosed |
| WO-2021028643-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| US-10864279-B2 | Linker-drug and antibody-drug conjugate (ADC) employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-12-15 | — | — | US | disclosed |
| US-10865183-B2 | Compounds, reagents, and uses thereof | METABOLON, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| CN-112010822-A | Method for preparing chiral gamma-amino alcohol and chiral alpha-allyl alcohol by one-pot method | 南方科技大学 | 2020-12-01 | — | — | CN | disclosed |
| US-20200361944-A1 | FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES | ZEALAND PHARMA A/S (DK) | 2020-11-19 | — | — | US | disclosed |
| US-20200362022-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES | PINTEON THERAPEUTICS INC. (US) | 2020-11-19 | — | — | US | disclosed |
| WO-2020222011-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | disclosed |
| EP-3444237-B1 | IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-20200291134-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2020-09-17 | — | — | US | disclosed |
| EP-3706795-A2 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES | Pinteon Therapeutics Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| EP-2968548-B1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111587123-A | Methods and compositions for generating and using humanized conformation-specific phosphorylated tau antibodies | 品通治疗有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| WO-2020145250-A1 | 15-PGDH INHIBITOR | 杏林製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200131119-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF TASMANIA (AU) | 2020-04-30 | — | — | US | disclosed |
| US-20200095259-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-03-26 | — | — | US | disclosed |
| EP-3615502-A1 | THERAPEUTIC COMPOUNDS AND METHODS | University Of Tasmania (AU) | 2020-03-04 | — | — | EP | disclosed |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3599236-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20190345135-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-11-14 | — | — | US | disclosed |
| CN-107629061-B | A kind of fluoro (±)-PenibrugiueramineA and its synthesis and the application as antibacterials | 江西师范大学 | 2019-11-08 | — | — | CN | disclosed |
| CN-107629061-B | A kind of fluoro (±)-PenibrugiueramineA and its synthesis and the application as antibacterials | 江西师范大学 | 2019-11-08 | — | — | CN | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| CN-110339351-A | The stabilizer that a kind of preparation method of veterinary rabies inactivated vaccine and the vaccine include | 武汉科前生物股份有限公司 | 2019-10-18 | — | — | CN | disclosed |
| WO-2019195720-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-10336769-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3202460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190152907-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | METABOLON, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| CN-108025574-B | Thermal recording medium | 三光株式会社 | 2019-04-16 | — | — | CN | disclosed |
| EP-3106460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190077805-A1 | Fragment Synthesis of Cyclic Peptides | ZEALAND PHARMA A/S (DK) | 2019-03-14 | — | — | US | disclosed |
| CN-106061971-B | Pyrrolidinyl sulfone derivatives and their use as ROR gamma modulators | 百时美施贵宝公司 | 2019-03-12 | — | — | CN | disclosed |
| EP-3444237-A1 | IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| US-10189814-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| CN-109232713-A | Nmda receptor regulator and application thereof | 西北大学 | 2019-01-18 | — | — | CN | disclosed |
| EP-3202461-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180327449-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2018-11-15 | — | — | US | disclosed |
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | UNIV NORTHWESTERN (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2018191789-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF TASMANIA (AU) | 2018-10-25 | — | — | WO | disclosed |
| CN-105283196-B | For generate and using conformation-specific antibody method and composition | 贝丝以色列女执事医疗中心 | 2018-10-12 | — | — | CN | disclosed |
| US-10086634-B2 | Heat-sensitive recording material | SANKO CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| CN-108569991-A | A kind of preparation method of anti-hepatitis C virus key intermediate of medicament | 常州制药厂有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-104693193-B | Aryl methoxy isoindoline derivative and composition and their application method including it | 细胞基因公司 | 2018-09-18 | — | — | CN | disclosed |
| EP-2771021-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTH WESTERN UNIV (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180237474-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2018-08-23 | — | — | US | disclosed |
| EP-3362080-A1 | PHARMACEUTICAL COMBINATION OF AN ATYPICAL ANTIPSYCHOTIC AND AN NMDA MODULATOR FOR THE TREATMENT OF SCHIZOPHRENIA,BIPOLAR DISORDER, COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER | Northwestern University (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3342599-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Sanko Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| CN-108218755-A | A kind of synthesis technology of N-Boc-4- oxos-L-PROLINE tert-butyl ester | 上海仁实医药科技有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-108201625-A | Linker drugs and antibody drug complexes comprising the same | 财团法人工业技术研究院 | 2018-06-26 | — | — | CN | disclosed |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-06-21 | — | — | US | disclosed |
| EP-3335734-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | Industrial Technology Research Institute (TW) | 2018-06-20 | — | — | EP | disclosed |
| US-9994613-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9975903-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| CN-108025574-A | Thermal recording medium | 三光株式会社 | 2018-05-11 | — | — | CN | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072814-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9902730-B2 | Compounds and compositions as toll-like receptor 7 agonists | NOVARTIS AG (CH) | 2018-02-27 | — | — | US | disclosed |
| EP-2928883-B1 | PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS AND MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARM SPA (IT) | 2018-02-14 | — | — | EP | disclosed |
| US-20180037567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-02-08 | — | — | US | disclosed |
| WO-2018022866-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | METABOLON, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| CN-107629061-A | A kind of fluoro (±) PenibrugiueramineA and its synthesis and the application as antibacterials | 江西师范大学 | 2018-01-26 | — | — | CN | disclosed |
| WO-2017205964-A1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIVERSITé LAVAL (CA) | 2017-12-07 | — | — | WO | disclosed |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| CN-105037262-B | A kind of synthetic method of naphthalene substituted quinoline derivatives | 重庆天春科技有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-9828361-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-11-28 | — | — | US | disclosed |
| US-9822094-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| CN-104892506-B | A kind of synthetic method of polysubstituted chinoline compound | 吴丽清 | 2017-11-07 | — | — | CN | disclosed |
| EP-3239142-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796784-B2 | Methods and compositions for the generation and use of conformation-specific antibodies | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3202461-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3202460-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3191502-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | Seattle Genetics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| CN-104744491-B | Benzo oxazepine * PI3K inhibitor compounds and application method | 霍夫曼-拉罗奇有限公司 | 2017-07-11 | — | — | CN | disclosed |
| US-9688747-B2 | Methods and compositions for the generation and use of conformation-specific antibodies | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| CN-104854086-B | Heterocyclic amide derivative and drug containing the same | EA制药株式会社 | 2017-06-27 | — | — | CN | disclosed |
| EP-2536706-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9670228-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| CN-106715418-A | Therapeutic compounds and methods of use thereof | 基因泰克公司 | 2017-05-24 | — | — | CN | disclosed |
| WO-2017079821-A1 | FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES | ENCYCLE THERAPEUTICS, INC. (CA) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017066590-A1 | PHARMACEUTICAL COMBINATION OF AN ATYPICAL ANTIPSYCHOTIC AND AN NMDA MODULATOR FOR THE TREATMENT OF SCHIZOPHRENIA,BIPOLAR DISORDER, COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER | NORTHWESTERN UNIVERSITY (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066590-A1 | PHARMACEUTICAL COMBINATION OF AN ATYPICAL ANTIPSYCHOTIC AND AN NMDA MODULATOR FOR THE TREATMENT OF SCHIZOPHRENIA,BIPOLAR DISORDER, COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER | NORTHWESTERN UNIVERSITY (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-3137470-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | Novartis AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170057968-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2017-03-02 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2017-01-26 | — | — | US | disclosed |
| US-9546178-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| EP-3106460-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160362445-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-12-15 | — | — | US | disclosed |
| US-9487555-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-08 | — | — | US | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9422310-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-9388212-B2 | Solid phase peptide synthesis via side chain attachment | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-07-12 | — | — | US | disclosed |
| US-20160159768-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159772-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-9328112-B2 | Tetracyclic CDK9 kinase inhibitors | ABBVIE INC. (US) | 2016-05-03 | — | — | US | disclosed |
| EP-3006441-A1 | NS5A INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9309219-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9290487-B2 | Pharmaceutical composition for treating diabetes | AJINOMOTO CO., INC. (JP) | 2016-03-22 | — | — | US | disclosed |
| WO-2016040684-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160052933-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160031977-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| CN-105283196-A | Methods and compositions for the generation and use of conformation-specific antibodies | BETH ISRAEL HOSPITAL | 2016-01-27 | — | — | CN | disclosed |
| US-9242013-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242013-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2970264-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968548-A2 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | Beth Israel Deaconess Medical Center, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-9198918-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| CN-103827133-B | Estra-1, 3,5(10), 16-tetraene-3-carboxamide derivatives, method for the production thereof, pharmaceutical preparations containing the same, and use thereof for producing medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| CN-105101947-A | Dyeing method using iridoid compound and apparatus therefor | OREAL | 2015-11-25 | — | — | CN | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150322066-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-12 | — | — | US | disclosed |
| US-20150322066-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-12 | — | — | US | disclosed |
| US-20150322066-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-12 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| WO-2015168269-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015164289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-2937335-A1 | HETEROCYCLIC AMIDE DERIVATIVE, AND MEDICINE CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169245-B2 | Inhibitors of PDE4 enzyme and antagonists of muscarinic M3 receptor | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-10-27 | — | — | US | disclosed |
| US-9169245-B2 | Inhibitors of PDE4 enzyme and antagonists of muscarinic M3 receptor | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-10-27 | — | — | US | disclosed |
| US-9156880-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150284375-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | disclosed |
| US-9150587-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150587-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150218165-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9090618-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090618-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090618-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| CN-102906098-B | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI AVENTIS | 2015-07-15 | — | — | CN | disclosed |
| EP-2270005-B1 | Prodrug of an ice inhibitor | VERTEX PHARMA (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2015-07-02 | — | — | US | disclosed |
| CN-104744491-A | Benzoxazepin Pi3k Inhibitor Compounds And Methods Of Use | HOFFMAN LA ROCHE AG | 2015-07-01 | — | — | CN | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| CN-102834399-B | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI SA | 2015-04-22 | — | — | CN | disclosed |
| CN-102762576-B | Benzoxazepine PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2015-04-22 | — | — | CN | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2845592-A1 | Benzoxazepin PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-8952161-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150038683-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2015-02-05 | — | — | US | disclosed |
| CN-104321071-A | Nmda receptor modulators and uses thereof | UNIV NORTHWESTERN | 2015-01-28 | — | — | CN | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2155194-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2014200885-A1 | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371455-A1 | Chemical compounds | JANSSEN PHARMACEUTICALS INC (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371455-A1 | Chemical compounds | JANSSEN PHARMACEUTICALS INC (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20140343098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8853416-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853416-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846690-B2 | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| WO-2014152157-A2 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETHISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014151444-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2774917-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | Ajinomoto Co., Inc. (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140242100-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140235789-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2014-08-21 | — | — | US | disclosed |
| US-8802700-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8771693-B2 | Methods and compositions for the generation and use of conformation-specific antibodies | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014102594-A2 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| WO-2014086855-A1 | PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-20140155373-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-05 | — | — | US | disclosed |
| US-20140155373-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-05 | — | — | US | disclosed |
| CN-103827133-A | Estra-1, 3,5(10), 16-tetraene-3-carboxamide derivatives, method for the production thereof, pharmaceutical preparations containing the same, and use thereof for producing medicaments | BAYER IP GMBH | 2014-05-28 | — | — | CN | disclosed |
| US-8691848-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-08 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| CN-101835757-B | Diacylglycerol acyltransferase inhibitors | HOFFMANN LA ROCHE | 2014-03-05 | — | — | CN | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140024665-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-8618286-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-12-31 | — | — | US | disclosed |
| EP-2483278-B1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8614205-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-12-24 | — | — | US | disclosed |
| US-8614327-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130336920-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130331310-A1 | Prodrug of an Ice Inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-12 | — | — | US | disclosed |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2523959-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-8586574-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013163466-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130274304-A1 | Chemical Compounds | Janssen Pharmaceuticals, Inc. | 2013-10-17 | — | — | US | disclosed |
| US-20130274304-A1 | Chemical Compounds | Janssen Pharmaceuticals, Inc. | 2013-10-17 | — | — | US | disclosed |
| EP-2523960-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-10-16 | — | — | EP | disclosed |
| US-8536136-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| EP-1781664-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8492554-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492554-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481738-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-27 | — | — | US | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20130150416-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD D (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590656-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130072502-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| US-20130072690-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072690-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130028900-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| CN-102906098-A | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI AVENTIS | 2013-01-30 | — | — | CN | disclosed |
| US-8354427-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-8343955-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344155-B2 | Chemical compounds | GLAXOSMITH KLINE LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344155-B2 | Chemical compounds | GLAXOSMITH KLINE LLC (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-8329662-B2 | Prodrug of an ICE inhibitor | Vertexd Pharmaceuticals Incorporated (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| EP-2523960-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523959-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2012149334-A2 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| CN-102762576-A | Benzoxazepine PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2012-10-31 | — | — | CN | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2012-09-27 | — | — | US | disclosed |
| CN-101031570-B | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2012-09-05 | — | — | CN | disclosed |
| US-8258159-B2 | Inhibitors of the α2β1/GPIa-IIa integrin | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258159-B2 | Inhibitors of the α2β1/GPIa-IIa integrin | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258159-B2 | Inhibitors of the α2β1/GPIa-IIa integrin | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-8242104-B2 | Benzoxazepin P13K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-14 | — | — | US | disclosed |
| EP-2483278-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-8211882-B2 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-8115011-B2 | (S)-3-{5-[(1-Pyridin-2-yl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-ylamino}-pyrrolidine-1-carboxylic acid ethyl ester; obesity, type II diabetes mellitus and metabolic syndrome | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| EP-1396492-B1 | Prodrug of an ice inhibitor | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1286989-B1 | Prodrug of an ICE inhibitor | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-8084614-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110301096-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-8058299-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-8022041-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-20 | — | — | US | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| WO-2011086080-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086078-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| US-20110151006-A1 | STIMULI-RESPONSIVE HYDROGEL | ETH ZURICH (CH) | 2011-06-23 | — | — | US | disclosed |
| WO-2011056561-A1 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| WO-2011028596-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110044974-A1 | Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-2285418-A1 | STIMULI-RESPONSIVE HYDROGEL | ETH Zurich (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2270005-A1 | Prodrug of an ice inhibitor | Vertex Pharmceuticals Incorporated (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100330109-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101072779-B | 2,4(4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA NV | 2010-12-22 | — | — | CN | disclosed |
| EP-2261235-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261234-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261233-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261232-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-20100256333-A1 | Peptide-Based Beta Turn Mimetics | UNIVERSITY OF MANITOBA (CA) | 2010-10-07 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010107832-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107832-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2010-09-23 | — | — | WO | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2010101648-A1 | GLUTAMATE RECEPTOR MODULATORS AND THERAPEUTIC AGENTS | WOOD RICHARD D (US) | 2010-09-10 | — | — | WO | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7781443-B2 | cholesteryl ester transfer protein (CETP) anatgonists such as 2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester, having improved bioavailability | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| EP-2076494-B1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-28 | — | — | EP | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-08 | — | — | US | disclosed |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7683033-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2155194-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009146929-A1 | STIMULI-RESPONSIVE HYDROGEL | ETH Zürich (CH) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-7612068-B2 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| WO-2009126624-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | WOOD RICHARD DELAREY | 2009-09-24 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-2076494-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| EP-2049483-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1635816-B1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX SA (FR) | 2009-03-04 | — | — | EP | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| EP-2011800-A2 | Inhibitors of caspase | Vertex Pharmaceuticals Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080312080-A1 | Novel dioctatin derivatives and production process thereof | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7462637-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462637-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462637-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2008124610-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1064298-B1 | INHIBITORS OF CASPASES | VERTEX PHARMA (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| EP-1939625-A2 | Methods for ligand discovery | Sunesis Pharmaceuticals, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008049806-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-02 | — | — | WO | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1893573-A1 | INHIBITORS OF HCV REPLICATION | Brystol-Myers Squibb Company (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | PITLIK JANOS | 2007-12-20 | — | — | US | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| CN-101072779-A | 2,4(4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2007-11-14 | — | — | CN | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| US-7217733-B2 | ACE inhibitor derivatives | NICOX, S.A. (FR) | 2007-05-15 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2007025776-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1732924-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006133338-A1 | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006133326-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
| US-7132418-B2 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1244446-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1192133-B1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20060166894-A1 | Ace-inhibitors having antioxidant and no-donor activity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-07-27 | — | — | US | disclosed |
| CN-1809345-A | Enalapril-nitroxyderivatives derivatives and related compounds as ACE inhibitors for the treatment of cardiovascular diseases | NICOX SA (FR) | 2006-07-26 | — | — | CN | disclosed |
| US-20060120980-A1 | Novel dermatological composition using bio-activating organocatalysts | EBERSYTES, LLC | 2006-06-08 | — | — | US | disclosed |
| CN-1780841-A | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the traetment of hypertension | PFIZER LTD (GB) | 2006-05-31 | — | — | CN | disclosed |
| US-7045360-B2 | Method for analysis of reaction products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1635816-A1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| EP-1631586-A2 | PEPTIDE ANALOGUES COMPRISING AT LEAST ONE TYPE OF AMINOACYL AZA-BETA 3 AND THE USE THEREOF, IN PARTICULAR FOR THERAPY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-03-08 | — | — | EP | disclosed |
| US-6998233-B2 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622868-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-02-08 | — | — | EP | disclosed |
| EP-1620437-A1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-20050250743-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | LEHN JEAN-MARIE | 2005-11-10 | — | — | US | disclosed |
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005095395-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-6953805-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| EP-1578413-A2 | ACE-INHIBITORS HAVING ANTIOXIDANT AND NO-DONOR ACTIVITY | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2005-09-28 | — | — | EP | disclosed |
| US-20050170999-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | FILLA SANDRA A (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1558248-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-20050142614-A1 | Methods for ligand discovery | WELLS JIM (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | disclosed |
| US-6887870-B1 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1446496-A4 | METHODS FOR LIGAND DISCOVERY | SUNESIS PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20050054704-A1 | Derivatives of [6,7-dihydro-5H- Imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-6858630-B2 | Naphthimidazole derivatives and their use as thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| CN-1582151-A | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2005-02-16 | — | — | CN | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| US-6852748-B1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6852752-B2 | Urea compounds, compositions and methods of use and preparation | VICURON PHARMACEUTICALS INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-6846820-B2 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20050004100-A1 | ACE inhibitor derivatives | NICOX S.A. (FR) | 2005-01-06 | — | — | US | disclosed |
| WO-2004111086-A2 | PEPTIDE ANALOGUES COMPRISING AT LEAST ONE TYPE OF AMINOACYL AZA-$G(B)3 AND THE USE THEREOF, IN PARTICULAR FOR THERAPY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (FR) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110432-A1 | ENALAPRIL-NITROXYDERIVATIVES DERIVATIVES AND RELATED COMPOUNDS AS ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004096761-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1446496-A2 | METHODS FOR LIGAND DICOVERY | Sunesis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2004050084-A2 | ACE-INHIBITORS HAVING ANTIOXIDANT AND NITRICOXID-DONOR ACTIVITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-06-17 | — | — | WO | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2004041273-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-1396492-A1 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20040043426-A1 | Methods for ligand discovery | WELLS JIM (US) | 2004-03-04 | — | — | US | disclosed |
| CN-1134264-C | antithrombotic agent | — | 2004-01-14 | — | — | CN | disclosed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030232986-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1361212-A1 | Peptide derivatives as antithrombotic agents | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| EP-0923566-B1 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6638941-B1 | Spirolactam compounds useful as inhibitors of protein-protein interactions modulated by SH3 domains are disclosed. Compounds of the invention are also useful as beta-turn mimetics. Disclosed are libraries of compounds of the invention, and | OSI PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1351951-A2 | PYRROLIDINYLMETHYL- AND PIPERIDINYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-0672658-B1 | Antithrombotic agents | ASTRAZENECA AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6610702-B2 | Supplying oxygen to tissues, organs | GMP OXYCELL, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1252141-B1 | TOSYLPROLINE ANALOGS AS THYMIDYLATE SYNTHASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-6593346-B2 | Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. | MERCK & CO. INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| WO-2003051848-A2 | IMIDAZOLIDINEACETIC ACID DERIVATIVES | FERRING BV (NL) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003046200-A2 | METHODS FOR LIGAND DISCOVERY | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1289993-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6531474-B1 | Treating inflammatory disease, osteoarthritis, glomerulonephritis, rheumatoid arthritis, psoriasis, graft vs. host disease, sepsis, or septic shock | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-11 | — | — | US | disclosed |
| EP-1286989-A2 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6512001-B1 | To treat diseases associated with amyloidosis, such as Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2003-01-28 | — | — | US | disclosed |
| US-6506908-B2 | From bicyclo(3.1.0)hexabe; decyclization; decarboxylation | MERCK & CO., INC. | 2003-01-14 | — | — | US | disclosed |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244446-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6500842-B1 | N-((4-CHLOROPHENYL)METHYL)-8-HYDROXY-7-QUINOLINECARBOXAMIDE ADMINISTERED AS VIRICIDES AGAINST HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020173494-A1 | Ammonium salts of inositol hexaphosphate, and uses thereof | GMP OXYCELL, INC. | 2002-11-21 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1252141-A1 | TOSYLPROLINE ANALOGS AS THYMIDYLATE SYNTHASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-6472410-B1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020155505-A1 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6469036-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH THE RESPIRATORY TRACT, SUCH AS ASTHMA AND ALLERGIC RHINITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-1244446-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020120146-A1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-08-29 | — | — | US | disclosed |
| US-20020119962-A1 | Novel urea compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-29 | — | — | US | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| US-20020090728-A1 | Method for analysis of reaction products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-07-11 | — | — | US | disclosed |
| WO-2002053555-A2 | PYRROLIDINYLMETHYL- AND PIPERIDINYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| EP-1192133-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1041980-A4 | ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358979-B1 | FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| EP-1183235-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2002014349-A2 | NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| US-20020016492-A1 | Process for preparing 3-hydroxymethyl-4-(aryl or heterocyclic)-cyclopentanones | MERCK SHARP & DOHME CORP. | 2002-02-07 | — | — | US | disclosed |
| US-20020013278-A1 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2002-01-31 | — | — | US | disclosed |
| EP-0685489-B1 | Tripeptide antithrombotic agents | LILLY CO ELI (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001094351-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001090063-A2 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6310211-B1 | ANTI-VIRAL ACTIVITY AGAINST HERPES VIRUS, CYTOMEGALOVIRUS. MANY OF THESE COMPOUNDS ARE ALSO ACTIVE AGAINST VARICELLA ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HERPES SIMPLEX VIRUS AND HUMAN HERPES VIRUS TYPE 8 | PHARMACIA & UPJOHN COMPANY | 2001-10-30 | — | — | US | disclosed |
| EP-0923566-A4 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON INC (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| WO-2001056987-A1 | TOSYLPROLINE ANALOGS AS THYMIDYLATE SYNTHASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001057526-A1 | METHOD FOR ANALYSIS OF REACTION PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6271252-B1 | ASTHMA THERAPY, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS,MULTIPLE SCLEROSIS, AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-08-07 | — | — | US | disclosed |
| US-6252080-B1 | HERPES, CYTOMEGALO VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-06-26 | — | — | US | disclosed |
| WO-2001044178-A1 | NOVEL UREA COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001039773-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6242262-B1 | MIXING DISCRETE SOLID SUPPORTS, EACH HAVING DIFFERENT ORGANIC COMPOUND, WITH REACTION SOLUTION SO THAT SUPPORTS ARE AT AN INTERFACE IN VESSEL; THEN DETECTING TEMPERATURE CHANGE OF A SOLID SUPPORT AS INDICATION OF AN ACTIVE CATALYST | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-06-05 | — | — | US | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-6214841-B1 | ANTICOAGULANTS | ELI LILLY AND COMPANY | 2001-04-10 | — | — | US | disclosed |
| US-6211376-B1 | HERPES VIRUS, CYTOMEGALO VIRUS, VARICELLA-ZOSTER VIRUS,EPSTEIN-BARR VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-04-03 | — | — | US | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000071510-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| US-6143776-A | Tosylproline analogs as thymidylate synthase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-1041980-A1 | ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6127355-A | LINKING COMPOUNDS WHICH CAN JOIN ACTIVE DRUGS(OR DERIVATIVES)TO POLYETHERS OR ALKYL OR CYCLOALKYL GROUPS, FOR WATER SOLUBILITY OR STABILIZATION, DRUG DELIVERY | ENZON, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1033983-A1 | CYCLIC AMINO ACID DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
| EP-0991619-A1 | INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| US-6011059-A | PREVENTING OR TREATING ANGINA PECTORIS, CARDIAC DYSFUNCTION, MYOCARDIAL NECROSIS, AND ARRHYTHMIA EMPLOYING THE ABOVE ACYL GUANIDINES. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| US-5998410-A | Sulfonamide derivatives | ONO PHARMACEUTICALS CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| US-5965700-A | Preparation of active peptides | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| US-5965566-A | A WATER SOLUBLE BIOLOGICAL ACTIVE DRUG CONJUGATED WITH POLYOXYETHYLENE GLYCOL THROUGH A HYDROLYZABLE ESTER LINKAGING SPACER; CONTROLLED RELEASE PROPERTIES | ENZON, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0842190-B1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AG (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999021957-A9 | METHOD AND APPARATUS FOR SCREENING CATALYST LIBRARIES | UNIV NORTH CAROLINA (US) | 1999-08-12 | — | — | WO | disclosed |
| US-5929114-A | ADMINISTERING ANTIVIRAL COMPOUND WHICH EXTRUDES ZINC FROM NUCLEOCAPSID PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS | WARNER-LAMBERT COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1999033460-A1 | ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-07-08 | — | — | WO | disclosed |
| EP-0927164-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0923566-A1 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON, INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5914319-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| EP-0661986-B1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIV FLORIDA (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999026615-A1 | CYCLIC AMINO ACID DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999021957-A1 | METHOD AND APPARATUS FOR SCREENING CATALYST LIBRARIES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5877030-A | REACTING AMINO ACID MOLECULES WITH REACTIVE XANTHENE DERIVATIVES, COMBINATORIAL LIBRARIES | SILICON VALLEY BANK | 1999-03-02 | — | — | US | disclosed |
| WO-1998058902-A1 | INHIBITORS OF α4β1MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-30 | — | — | WO | disclosed |
| EP-0884326-A2 | Antithrombitic compound | ELI LILLY AND COMPANY (US) | 1998-12-16 | — | — | EP | disclosed |
| US-5847155-A | Aromatic pyrrolidine amide prolyl endopeptidase inhibitors | PFIZER INC (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998054208-A1 | CONFORMATIONALLY CONSTRAINED PEPTIDOMIMETICS AS β-TURN TEMPLATES AND MODULATORS OF SH3 DOMAINS | CADUS PHARMACEUTICAL CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5840900-A | POLYETHERS, POLYAMIDE POLYMERS WITH PRODRUGS | ENZON, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998051684-A1 | ANTITHROMBOTIC COMPOUND | ELI LILLY AND COMPANY (US) | 1998-11-19 | — | — | WO | disclosed |
| EP-0877753-A1 | PEPTIDE INHIBITORS OF HEMATOPOIETIC CELL PROLIFERATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (FR) | 1998-11-18 | — | — | EP | disclosed |
| EP-0598899-B1 | LIQUID PHASE SYNTHESIS OF PEPTIDES AND PEPTIDE DERIVATIVES | KINERTON LTD (IE) | 1998-09-30 | — | — | EP | disclosed |
| EP-0670310-B1 | Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants | LILLY CO ELI (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5795890-A | ELASTASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-08-18 | — | — | US | disclosed |
| US-5760235-A | DIPEPTIDES BASED ON PROLINE OR PIPECOLIC ACID AND ARGININE ALDEHYDE | GYOGYSZERKUTATO INTEZET KFT. (HU) | 1998-06-02 | — | — | US | disclosed |
| EP-0842190-A1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0837071-A1 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| US-5734081-A | Arylthio compounds | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1998011073-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5726159-A | PEPTIDE THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1998007713-A1 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
| US-5710130-A | HETEROCYCLIC SYNTHETIC PEPTIDES | ELI LILLY AND COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| US-5707966-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5705487-A | PEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0643073-B1 | Tripeptide antithrombotic agents | LILLY CO ELI (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5688946-A | DIPEPTIDES FOR HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | HOFFMANN LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0629212-B1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF | GYOGYSZERKUTATO INTEZET (HU) | 1997-10-08 | — | — | EP | disclosed |
| US-5668291-A | THIOSUBSTITUTED PYRIDINES, TREATMENT OF AIDS AND HIV | WARNER-LAMBERT COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| CN-1159188-A | Herbicidal pyrazine derivatives | BASF AG (DE) | 1997-09-10 | — | — | CN | disclosed |
| WO-1997028183-A1 | PEPTIDE INHIBITORS OF HEMATOPOIETIC CELL PROLIFERATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (S.C.R.A.S.) (FR) | 1997-08-07 | — | — | WO | disclosed |
| US-5652369-A | PROTEASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0775110-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5624894-A | Brain-enhanced delivery of neuroactive peptides by sequential metabolism | UNIVERSITY OF FLORIDA (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0661986-A4 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM. | UNIV FLORIDA (US) | 1997-04-23 | — | — | EP | disclosed |
| US-5620987-A | Amino acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1997005162-A1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5561133-A | Thymidylate synthase inhibiting quinazolinones | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-10-01 | — | — | US | disclosed |
| US-5554756-A | PROTEASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-5518735-A | ANTICOAGULANTS ADMINISTERED BY MOUTH | PENTAPHARM AG (CH) | 1996-05-21 | — | — | US | disclosed |
| US-5516891-A | COUPLING 9-FLUORENYLMETHOXYCARBONYL PROTECTED AMINO ACIDS INSOLVENT CONTAINING CARBODIIMIDE; AMIDATION | KINERTON, LTD. (IE) | 1996-05-14 | — | — | US | disclosed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0267723-B1 | New substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents | MERCK & CO INC (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0685489-A2 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0684258-A2 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5459156-A | Angiotensin converting enzyme inhibitors, hypotensive, atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| EP-0670310-A1 | Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants | ELI LILLY AND COMPANY (US) | 1995-09-06 | — | — | EP | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995019359-A1 | PROCESS FOR MAKING XANTHENE OR CUBANE BASED COMPOUNDS, AND PROTEASE INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1995-07-20 | — | — | WO | disclosed |
| EP-0661986-A1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIVERSITY OF FLORIDA (US) | 1995-07-12 | — | — | EP | disclosed |
| US-5430023-A | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-07-04 | — | — | US | disclosed |
| US-5426103-A | Endopeptidase inhibitors; condensing macrocylic compound with a thioic acid or salt therof; possible esterification, salt formation, deslating, deprotecting, deesterifying of function-al groups | CIBA-GEIGY CORPORATION (US) | 1995-06-20 | — | — | US | disclosed |
| US-5407916-A | Oligopeptides for use as analgesics or antipsychotic agents | WARNER-LAMBERT COMPANY (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0643073-A1 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1995004740-A1 | 7α-AMINO-1,1-DIOXOCEFEM L-VALYLAMIDES | DOMPE' S.P.A. (IT) | 1995-02-16 | — | — | WO | disclosed |
| US-5380713-A | Serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0631576-A1 | DIPEPTIDYLQUINAZOLONES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1995-01-04 | — | — | EP | disclosed |
| EP-0629212-A1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF. | GYOGYSZERKUTATO INTEZET (HU) | 1994-12-21 | — | — | EP | disclosed |
| US-5364848-A | Elastase inhibitors | MERCK & CO., INC. (US) | 1994-11-15 | — | — | US | disclosed |
| WO-1994024095-A1 | IMMUNOSUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0618894-A1 | NEW TETRAHYDRONAPHTHALENE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1994-10-12 | — | — | EP | disclosed |
| EP-0606003-A1 | Method for minimizing and containing ischemic and reperfusion injury | ELI LILLY AND COMPANY (US) | 1994-07-13 | — | — | EP | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| WO-1994006450-A1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIVERSTIY OF FLORIDA (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0291234-B1 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC (US) | 1994-03-23 | — | — | EP | disclosed |
| EP-0581789-A1 | NOVEL 2-SPIROCYCLOPROPYL CEPHALOSPORIN SULFONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | SYNPHAR LABORATORIES INC. (CA) | 1994-02-09 | — | — | EP | disclosed |
| US-5264430-A | Enzyme inhibitor, antiinflammatory agents, treats emphysema, cystic fibrosis and arthritis | SYNPHAR LABORATORIES, INC. (CA) | 1993-11-23 | — | — | US | disclosed |
| US-5264429-A | Enzyme inhibitor, antiinflammatory agents, treats emphysema, cystic fibrosis and arthritis | SYNPHAR LABORATORIES, INC. (CA) | 1993-11-23 | — | — | US | disclosed |
| US-5250660-A | Peptide purification process | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| WO-1993019051-A1 | DIPEPTIDYLQUINAZOLONES AS ANTI-CANCER AGENTS | BRITISH TECHNOLOGY GROUP LTD (GB) | 1993-09-30 | — | — | WO | disclosed |
| WO-1993018060-A1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF | Gyógyszerkutató Intézet Kft. (HU) | 1993-09-16 | — | — | WO | disclosed |
| US-5244889-A | Treatment of cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0557936-A1 | Amidic derivatives of (R)-glycerophosphoryl-(S)-serine or of its diacyl derivative, process for their preparation and relative pharmaceutical compositions for the improvement of the learning processes | MAGIS FARMACEUTICI S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| EP-0556405-A1 | PSEUDOPENTAPEPTIDES WITH IMMUNOMODULATING ACTIVITY | Japan Tobacco Inc. (JP) | 1993-08-25 | — | — | EP | disclosed |
| WO-1993012070-A1 | NEW TETRAHYDRONAPHTHALENE DERIVATIVES | RICHTER GEDEON VEGYSZETI GYÁR RT. (HU) | 1993-06-24 | — | — | WO | disclosed |
| EP-0544620-A1 | Macrocyclic lactams as inhibitors of atrial natriuretic factors (ANF)-degrading neutral endopeptidase (NEP) | CIBA-GEIGY AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| EP-0536163-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| US-5202416-A | Substituted di-, tri- or tetrapeptides which may be supported on matrix, for chromatographic separations | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1993-04-13 | — | — | US | disclosed |
| EP-0355572-B1 | PEPTIDE DERIVATIVES, THEIR PRODUCTION AND USE | BEHRINGWERKE Aktiengesellschaft (DE) | 1993-03-17 | — | — | EP | disclosed |
| WO-1993004080-A1 | PSEUDOPENTAPEPTIDES WITH IMMUNOMODULATING ACTIVITY | JAPAN TOBACCO INC. (JP) | 1993-03-04 | — | — | WO | disclosed |
| EP-0526877-A2 | Peptide aldehydes as antithrombotic agents | Bristol-Myers Squibb Company (US) | 1993-02-10 | — | — | EP | disclosed |
| EP-0511347-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | Pentapharm A.G. (CH) | 1992-11-04 | — | — | EP | disclosed |
| WO-1992018474-A2 | NOVEL 2-SPIROCYCLOPROPYL CEPHALOSPORIN SULFONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | SYNPHAR LABORATORIES, INC. (CA) | 1992-10-29 | — | — | WO | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992016549-A1 | PARASUBSTITUTED PHENYLALANINE DERIVATES | PENTAPHARM AG (CH) | 1992-10-01 | — | — | WO | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| EP-0189305-B1 | PEPTIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| US-5132301-A | Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents | MERCK & CO., INC. (US) | 1992-07-21 | — | — | US | disclosed |
| WO-1992008709-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | PENTAPHARM AG (CH) | 1992-05-29 | — | — | WO | disclosed |
| US-5106997-A | For nonlinear optical elements, storage stability, heat and light resistant | FUJI XEROX CO., LTD. (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0479489-A2 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0204571-B1 | SELECTED DIFLUORO DERIVATIVES | ICI AMERICAS INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| WO-1991018891-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0416373-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-03-13 | — | — | EP | disclosed |
| US-4992541-A | Antiinflammatory, antidegenerative agents | MERCK & CO., INC. (US) | 1991-02-12 | — | — | US | disclosed |
| US-4977179-A | Inhibiting angiotensin converting enzyme | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-12-11 | — | — | US | disclosed |
| US-4954625-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-04 | — | — | US | disclosed |
| EP-0355572-A2 | Peptide derivatives, their production and use | BEHRINGWERKE Aktiengesellschaft (DE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| US-4886813-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1989-12-12 | — | — | US | disclosed |
| US-4871842-A | Piperidine derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-10-03 | — | — | US | disclosed |
| US-4866173-A | Therapeutic substituted semicarbazides | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
| US-4833152-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
| US-4816466-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-03-28 | — | — | US | disclosed |
| US-4801721-A | Stereospecific synthesis of carboxyalkyl peptides | RYAN JAMES W (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0291234-A2 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| EP-0083923-B1 | AMINOACYL-CONTAINING DIPEPTIDE DERIVATIVES USEFUL AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0267723-A2 | New substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents | MERCK & CO. INC. (US) | 1988-05-18 | — | — | EP | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
| US-4734420-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | UNIVERSITY OF MIAMI (US) | 1988-03-29 | — | — | US | disclosed |
| EP-0249349-A1 | Difluoroketo compounds | ICI AMERICAS INC. (US) | 1987-12-16 | — | — | EP | disclosed |
| US-4703037-A | Angiotensin-converting enzyme inhibitors | RORER PHARMACEUTICAL CORPORATION (US) | 1987-10-27 | — | — | US | disclosed |
| US-4698355-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-10-06 | — | — | US | disclosed |
| US-4698356-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-10-06 | — | — | US | disclosed |
| US-4695577-A | PEPTIDE, ANGIOTENSIN CONVERTING ENZYME INHIBITOR | UNIVERSITY OF MIAMI (US) | 1987-09-22 | — | — | US | disclosed |
| US-4695582-A | Inhibitors of angiotensin converting enzyme | UNIVERSITY OF MIAMI (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0237239-A2 | New compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-09-16 | — | — | EP | disclosed |
| US-4692458-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-09-08 | — | — | US | disclosed |
| US-4691007-A | HUMAN LEUKOCYTE ELASTASE INHIBITORS | ICI AMERICAS INC. (US) | 1987-09-01 | — | — | US | disclosed |
| US-4690937-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-09-01 | — | — | US | disclosed |
| US-4690936-A | AMINO ACIDS, THIOESTER LINKAGE; ANGIOTENSIN INHIBITORS | UNIVERSITY OF MIAMI (US) | 1987-09-01 | — | — | US | disclosed |
| US-4690939-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-09-01 | — | — | US | disclosed |
| US-4690938-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-09-01 | — | — | US | disclosed |
| US-4690940-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1987-09-01 | — | — | US | disclosed |
| US-4684660-A | Mercaptoacyldepeptides | E. R. SQUIBB & SONS, INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0084941-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-03-11 | — | — | EP | disclosed |
| US-4634715-A | CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0204571-A2 | Selected difluoro derivatives | ICI AMERICAS INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
| US-4602002-A | N-carboxymethyl substituted lysyl and α-(ε-aminoalkyl) glycyl amino acid antihypertensive agents | MERCK & CO., INC. (US) | 1986-07-22 | — | — | US | disclosed |
| EP-0187037-A2 | Piperidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-07-09 | — | — | EP | disclosed |
| US-4596789-A | Pharmaceuticals | ICI AMERICAS INC. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0061186-B1 | DIPEPTIDES CONTAINING THIALYSINE AND HOMOLOGS AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1986-05-21 | — | — | EP | disclosed |
| US-4585758-A | Angiotensin-converting enzyme inhibitors | USV PHARMACEUTICAL CORP. (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0035336-B1 | NOVEL PROCESSES FOR PREPARING PROLINE DERIVATIVES AND ANALOGOUS COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1986-04-09 | — | — | EP | disclosed |
| US-4578480-A | ANGIOTENSIN CONVERTING ENZYME INHUBITOR INTERMEDIATES | JOHN WYETH & BROTHER LIMITED (GB) | 1986-03-25 | — | — | US | disclosed |
| EP-0174162-A2 | Pharmaceutically active dipeptide derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-03-12 | — | — | EP | disclosed |
| EP-0058918-B1 | AZA ANALOGS OF AMINOACID DERIVATIVES AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1986-01-29 | — | — | EP | disclosed |
| US-4555502-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0073143-B1 | NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES | Ryan, James Walter (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0110225-B1 | BIS-(BENZOYLTHIO)-CARBOXYLIC ACIDS, THEIR PREPARATION AND USE IN THE PRODUCTION OF ACTIVE INGREDIENTS | BASF Aktiengesellschaft (DE) | 1985-10-23 | — | — | EP | disclosed |
| US-4512979-A | Dipeptides containing thialysine and related amino acids as antihypertensives | MERCK & CO., INC. (US) | 1985-04-23 | — | — | US | disclosed |
| US-4506082-A | DEESTERIFICATION WITH TRIFLUOROACETIC ACID | JOHN WYETH & BROTHER LIMITED (GB) | 1985-03-19 | — | — | US | disclosed |
| EP-0053017-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-20 | — | — | EP | disclosed |
| US-4500467-A | ANGIOTENSIN INHIBITORS, HYPOTENSIVE AGENTS | BASF AKTIENGESELLSCAFT (DE) | 1985-02-19 | — | — | US | disclosed |
| US-4496743-A | 1-[(Acylthiocycloalkyl)carbonyl]-L-proline derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1985-01-29 | — | — | US | disclosed |
| EP-0127124-A2 | Compounds for treating hypertension | USV PHARMACEUTICAL CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0127090-A2 | Angiotensin-converting enzyme inhibitors | USV PHARMACEUTICAL CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0124317-A2 | Proline derivatives | ICI AMERICAS INC. (US) | 1984-11-07 | — | — | EP | disclosed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | disclosed |
| EP-0110224-A2 | Benzoylthio compounds, their manufacture and use as medicines | BASF Aktiengesellschaft (DE) | 1984-06-13 | — | — | EP | disclosed |
| EP-0110225-A1 | Bis-(benzoylthio)-carboxylic acids, their preparation and use in the production of active ingredients | BASF Aktiengesellschaft (DE) | 1984-06-13 | — | — | EP | disclosed |
| EP-0109500-A1 | Therapeutic substituted semicarbazides | USV PHARMACEUTICAL CORPORATION (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0103496-A1 | Acylalkylaminocarbonyl substituted amino and imino acid compounds | E.R. Squibb & Sons, Inc. (US) | 1984-03-21 | — | — | EP | disclosed |
| EP-0045161-B1 | AMIDES OF 4-OXO-5-AMIDOHEXANOIC ACID DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-03-14 | — | — | EP | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0010347-B1 | NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1983-11-09 | — | — | EP | disclosed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | disclosed |
| US-4391752-A | Process for preparing 5H-pyrrolo[2,1-c]-[1,4]thiazepine-1,5-diones | JOHN WYETH AND BROTHER LIMITED (GB) | 1983-07-05 | — | — | US | disclosed |
| US-4385062-A | 1-[(-2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives, the process for their manufacture, the intermediates for their synthesis and their use as anti-hypertensive agents | GRUPPO LEPETIT S.P.A. (IT) | 1983-05-24 | — | — | US | disclosed |
| EP-0009898-B1 | NOVEL ANTI-HYPERTENSIVE MERCAPTOACYLAMINO ACID DERIVATIVES, THEIR PREPARATION AND USE | UNIVERSITY OF MIAMI (US) | 1983-05-18 | — | — | EP | disclosed |
| EP-0073143-A2 | Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides | Ryan, James Walter (US) | 1983-03-02 | — | — | EP | disclosed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0061186-A1 | Dipeptides containing thialysine and homologs as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4349480-A | Process for preparing 1-(3-bromo-2-alkylpropanoyl-L-proline derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1982-09-14 | — | — | US | disclosed |
| EP-0058918-A1 | Aza analogs of aminoacid derivatives as antihypertensives | MERCK & CO. INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| EP-0053017-A1 | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-06-02 | — | — | EP | disclosed |
| EP-0007477-B1 | 1-(3-MERCAPTO-2-METHYLPROPANOYL)PROLYL AMINO ACID DERIVATIVES AND SALTS THEREOF, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 1982-04-28 | — | — | EP | disclosed |
| EP-0049506-A1 | N-carboxyalkyl dipeptides, a process for preparing and a pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
| EP-0045161-A1 | Amides of 4-oxo-5-amidohexanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-02-03 | — | — | EP | disclosed |
| US-4308168-A | ALKYLESTERS OF AMINO ACIDS, NONTOXIC | IDEMITSU KOSAN CO., LTD. (JP) | 1981-12-29 | — | — | US | disclosed |
| US-4307110-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-12-22 | — | — | US | disclosed |
| EP-0038117-A1 | Methods for preparing anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1981-10-21 | — | — | EP | disclosed |
| EP-0036572-A1 | Substituted alkylthioacylamino acids, processes for their preparation and pharmaceutical compositions | C.H. BOEHRINGER SOHN (DE) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0035336-A2 | Novel processes for preparing proline derivatives and analogous compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1981-09-09 | — | — | EP | disclosed |
| EP-0000833-B1 | DERIVATIVES OF PHOSPHONOACYL PROLINES AND THEIR PHARMACEUTICAL USE | E.R. Squibb & Sons, Inc. (US) | 1981-09-02 | — | — | EP | disclosed |
| US-4284779-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | disclosed |
| US-4284780-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | disclosed |
| US-4248883-A | ANTIHYPERTENSION AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1981-02-03 | — | — | US | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |
| US-4241076-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1980-12-23 | — | — | US | disclosed |
| US-4228077-A | N-[2-(mercaptoalkyl)-3-mercaptoalkanoyl]-l-tryptophanes | E. R. SQUIBB & SONS, INC. (US) | 1980-10-14 | — | — | US | disclosed |
| US-4226775-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4221912-A | Dithio derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-4221706-A | B-ALANYL OR G-AMINOBUTYRYL-PROLYL-ARGINYL-P-NITROANILIDE, FOR QUANTITATIVE MEASUREMENT OF PROTEOLYTIC ENZYMES | ABBOTT LABORATORIES (US) | 1980-09-09 | — | — | US | disclosed |
| US-4217458-A | Acylmercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
| US-4206121-A | ANGIOTENSIN, ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1980-06-03 | — | — | US | disclosed |
| EP-0009898-A1 | Novel anti-hypertensive mercaptoacylamino acid derivatives, their preparation and use | UNIVERSITY OF MIAMI (US) | 1980-04-16 | — | — | EP | disclosed |
| US-4198515-A | Mercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-04-15 | — | — | US | disclosed |
| US-4198517-A | Histidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1980-04-15 | — | — | US | disclosed |
| EP-0007477-A1 | 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds | Dainippon Pharmaceutical Co., Ltd. (JP) | 1980-02-06 | — | — | EP | disclosed |
| US-4179434-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4178291-A | HYPOTENSIVE AGENTS, ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4177277-A | INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME | E. R. SQUIBB & SONS, INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4176235-A | ANGIOTENSIN COVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-11-27 | — | — | US | disclosed |
| US-4175199-A | Substituted acyl derivatives of amino acids | E. R. SQUIBB & SONS, INC. (US) | 1979-11-20 | — | — | US | disclosed |
| US-4168267-A | Phosphinylalkanoyl prolines | E. R. SQUIBB & SONS, INC. (US) | 1979-09-18 | — | — | US | disclosed |
| US-4165320-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-08-21 | — | — | US | disclosed |
| US-4156786-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-29 | — | — | US | disclosed |
| US-4154960-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4154946-A | Amino mercapto substituted acylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4154840-A | Antihypertensive pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4154736-A | Indolylalkylene amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4154937-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4154935-A | Halogen substituted mercaptoacylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4154936-A | ENZYME INHIBITORS, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4151172-A | Phosphonoacyl prolines and related compounds | E. R. SQUIBB & SONS, INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4146611-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4145549-A | CYCLIZATION, SOLVOLYSIS | SANDOZ LTD. (CH) | 1979-03-20 | — | — | US | disclosed |
| EP-0000833-A1 | Derivatives of phosphonoacyl prolines and their pharmaceutical use | E.R. Squibb & Sons, Inc. (US) | 1979-02-21 | — | — | EP | disclosed |
| US-4140864-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4129571-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4128721-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4128653-A | Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4127729-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4116962-A | ANGIOTENSIN CONVERTING ENXYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4113715-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4105776-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4091024-A | Pyrrolidine and piperidine-2-carboxylic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4086338-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4070361-A | Mercaptoalkylsulfonyl proline and pipecolic acid and esters thereof | E. R. SQUIBB & SONS, INC. (US) | 1978-01-24 | — | — | US | disclosed |
| US-4052511-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-04 | — | — | US | disclosed |
| US-4046889-A | HYPOTENSIVE AGENTS, ENZYME INHIBITORS, ANGIOTENSIN CONVERSION | E. R. SQUIBB & SONS, INC. (US) | 1977-09-06 | — | — | US | disclosed |
| US-3947575-A | Peptides as argiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
| US-3947575-A | Peptides as argiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS2 1/4885NOS3 3/4885NOS1 2/4885 |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | NOS2 3424/4885NOS3 2000/4885NOS1 3086/4885 |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOS2 1150/4885NOS3 1898/4885NOS1 1329/4885 |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | NOS2 2099/4885NOS3 2089/4885NOS1 1470/4885 |
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | NOS2 985/4885NOS3 1154/4885NOS1 2384/4885 |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | MPL, THPO, TPO | NOS2 347/4885NOS3 613/4885NOS1 290/4885 |
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | NOS2 1345/4885NOS3 1591/4885NOS1 303/4885 |
| US-12291524-B2 | Amido heteroaromatic compounds | CYP7A1, SLC10A1, CYP11B2 | NOS2 924/4885NOS3 1183/4885NOS1 1108/4885 |
| US-20040043426-A1 | Methods for ligand discovery | ADGRF1, VCAM1, LDLR | NOS2 4431/4885NOS3 4648/4885NOS1 4549/4885 |
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | NOS2 2654/4885NOS3 1555/4885NOS1 2456/4885 |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | NOS2 3646/4885NOS3 3409/4885NOS1 3440/4885 |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | NOS2 4803/4885NOS3 4746/4885NOS1 4841/4885 |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | NOS2 1345/4885NOS3 1591/4885NOS1 303/4885 |
| US-20090239919-A1 | Glutamate receptor modulators and therapeutic agents | GRM5, GRM1, GRIK5 | NOS2 2837/4885NOS3 2968/4885NOS1 2972/4885 |
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | NOS2 3279/4885NOS3 3711/4885NOS1 3878/4885 |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | NOS2 2654/4885NOS3 1555/4885NOS1 2456/4885 |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | NOS2 4611/4885NOS3 4540/4885NOS1 4638/4885 |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | NOS2 2398/4885NOS3 1654/4885NOS1 2976/4885 |
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | OPRL1, GRIN2A, GRM1 | NOS2 1445/4885NOS3 1499/4885NOS1 858/4885 |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | NOS2 2772/4885NOS3 1774/4885NOS1 2154/4885 |
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | ASIC1, SCN1A, NPR1 | NOS2 936/4885NOS3 662/4885NOS1 300/4885 |
| US-20100330109-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | NOS2 2759/4885NOS3 1725/4885NOS1 1819/4885 |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | IL1R1, IL1B, IL1A | NOS2 1171/4885NOS3 2192/4885NOS1 386/4885 |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | NOS2 3646/4885NOS3 3409/4885NOS1 3440/4885 |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | NOS2 840/4885NOS3 489/4885NOS1 533/4885 |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | NOS2 2784/4885NOS3 2039/4885NOS1 2169/4885 |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NOS2 3047/4885NOS3 2674/4885NOS1 4019/4885 |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | NOS2 4611/4885NOS3 4540/4885NOS1 4638/4885 |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | NOS2 2158/4885NOS3 2264/4885NOS1 1793/4885 |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | NOS2 1679/4885NOS3 558/4885NOS1 2347/4885 |
| US-20240115719-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | IGLV6-57, SSB, FCGR3B | NOS2 2177/4885NOS3 1469/4885NOS1 2396/4885 |
| US-20230303510-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLB, POLH | NOS2 3389/4885NOS3 4032/4885NOS1 3532/4885 |
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | CD274, PDCD1LG2, PDCD1 | NOS2 2706/4885NOS3 3778/4885NOS1 2533/4885 |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | NOS2 1709/4885NOS3 1949/4885NOS1 1444/4885 |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | NOS2 3944/4885NOS3 3697/4885NOS1 3589/4885 |
| US-20250382264-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | NR2C2, NR3C2, NPR1 | NOS2 167/4885NOS3 650/4885NOS1 360/4885 |
| US-20200131119-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UQCRC1, COX5B, CS | NOS2 669/4885NOS3 843/4885NOS1 718/4885 |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | QDPR, SBDS, DNPEP | NOS2 4803/4885NOS3 4746/4885NOS1 4841/4885 |
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | NOS2 3855/4885NOS3 3494/4885NOS1 3794/4885 |
| US-20150284375-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | TRPA1, TRPV1, TRPV2 | NOS2 775/4885NOS3 929/4885NOS1 790/4885 |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | NOS2 4803/4885NOS3 4746/4885NOS1 4841/4885 |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | NOS2 996/4885NOS3 977/4885NOS1 1013/4885 |
| US-20100256333-A1 | Peptide-Based Beta Turn Mimetics | VIP, PTMA, PREP | NOS2 1579/4885NOS3 2364/4885NOS1 2414/4885 |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | ITGA2B, ITGB2, ITGA2 | NOS2 3246/4885NOS3 4330/4885NOS1 3524/4885 |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | NOS2 3424/4885NOS3 2000/4885NOS1 3086/4885 |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | TYR, TPST2, COMT | NOS2 3278/4885NOS3 3266/4885NOS1 3100/4885 |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | NHERF1, SLC9A3, SLC9A1 | NOS2 1634/4885NOS3 488/4885NOS1 934/4885 |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | NOS2 4540/4885NOS3 4386/4885NOS1 4498/4885 |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | NOS2 2858/4885NOS3 3272/4885NOS1 3167/4885 |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS2 1/4885NOS3 3/4885NOS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.